| 1. |
Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2024, 99(4): 697-718. DOI: 10.1002/ajh.27216.
|
| 2. |
中華醫學會血液學分會白血病淋巴瘤學組. 原發性血小板增多癥診斷與治療中國專家共識(2016年版)[J]. 中華血液學雜志, 2016, 37(10): 833-836. DOI: 10.3760/cma.j.issn.0253-2727.2016.10.001.Leukemia and Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of essential thrombcythaemia (2016)[J]. Chin J Hematol, 2016, 37(10): 833-836. DOI: 10.3760/cma.j.issn.0253-2727.2016.10.001.
|
| 3. |
Liisborg C, Hasselbalch HC, S?rensen T. Ocular manifestations in patients with philadelphia-negative myeloproliferative neoplasms[J]. Cancers (Basel), 2020, 12(3): 573. DOI: 10.3390/cancers12030573.
|
| 4. |
中國免疫學會神經免疫分會. 抗髓鞘少突膠質細胞糖蛋白免疫球蛋白G抗體相關疾病診斷和治療中國專家共識[J]. 中國神經免疫學和神經病學雜志, 2020, 27(2): 86-95. DOI: 10.3969/j.issn.1006-2963.2020.02.002.Chinese Society of Immunology Neuroimmunology Branch. Chinese expert consensus on the diagnosis and treatment of diseases associated with anti-myelin oligodendrocyte glycoprotein immunoglobulin G antibodies[J]. Chin J Neuroimmunol&Neurol, 2020, 27(2): 86-95. DOI: 10.3969/j.issn.1006-2963.2020.02.002.
|
| 5. |
劉慧勤, 崔紅培, 張彌蘭, 等. 髓鞘少突膠質細胞糖蛋白抗體相關疾病的臨床、影像及預后特點[J]. 中華神經醫學雜志, 2022, 21(2): 164-171. DOI: 10.3760/cma.j.cn115354-20211216-00822.Liu HQ, Cui HP, Zhang ML, et al. Clinical and imaging features and prognoses of myelin oligodendrocyte glycoprotein antibody associated disorders[J]. Chin J Neuromed, 2022, 21(2): 164-171. DOI: 10.3760/cma.j.cn115354-20211216-00822.
|
| 6. |
Al-Ani A, Chen JJ, Costello F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges[J]. J Neurol, 2023, 270(8): 4132-4150. DOI: 10.1007/s00415-023-11737-8.
|
| 7. |
Moseley CE, Virupakshaiah A, Forsthuber TG, et al. MOG CNS autoimmunity and MOGAD[J/OL]. Neurol Neuroimmunol Neuroinflamm, 2024, 11(5): e200275[2024-07-12]. https://pubmed.ncbi.nlm.nih.gov/38996203/. DOI: 10.1212/NXI.0000000000200275.
|
| 8. |
Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria[J]. Lancet Neurol, 2023, 22(3): 268-282. DOI: 10.1016/S1474-4422(22)00431-8.
|
| 9. |
Uzawa A, Oertel FC, Mori M, et al. NMOSD and MOGAD: an evolving disease spectrum[J]. Nat Rev Neurol, 2024, 20(10): 602-619. DOI: 10.1038/s41582-024-01014-1.
|
| 10. |
Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis[J]. Curr Opin Neurol, 2020, 33(1): 47-54. DOI: 10.1097/WCO.0000000000000766.
|
| 11. |
Ambrosius W, Michalak S, Kozubski W, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management[J]. Int J Mol Sci, 2020, 22(1): 100. DOI: 10.3390/ijms22010100.
|
| 12. |
Takai Y, Yamagami A, Iwasa M, et al. Clinical features and prognostic factors in anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis[J]. Neuroophthalmology, 2024, 48(2): 134-141. DOI: 10.1080/01658107.2023.2287518.
|
